1 李淑青,陈亚萍.卵巢癌对顺铂和紫杉醇耐药的分子机制.国际妇产科学杂志,2016,43:145-150.
2 韦露薇,李力.上皮性卵巢癌多药耐药相关信号传导通路及其靶向药物研究进展.中国肿瘤临床,2016,43:396-399.
3 Seebacher V,Reinthaller A,Koelbl H,et al.The impact of the duration of adjuvant chemotherapy on survival in patients with epithelial ovarian cancer-a retrospective study.Plos One,2017,12:e0169272.
4 朱珏,张可,潘璐,等.遗传性卵巢癌综合征相关易感基因的研究进展.国际妇产科学杂志,2014:584-587.
5 李思瑾,张莘,徐国才,等.上皮性卵巢癌的病理类型与术后紫杉醇联合铂类化疗疗效以及预后的关系.广东医学,2017:2645-2648.
6 Jacob SL,Field HP,Calder N,et al.Anti‐Müllerian Hormone reflects the severity of Polycystic Ovary Syndrome.Clin Endocrinol,2017,86:395-400.
7 马丁.上皮性卵巢癌组织起源与肿瘤发生新进展“二元论”学说.中国实用妇科与产科杂志,2014,30:8-11.
8 Vang R,Levine DA,Soslow RA,et al.Molecular alterations of tp53 are a defining feature of ovarian high-grade serous carcinoma:a rereview of cases lacking tp53 mutations in the cancer genome Atlas Ovarian Study.Int J Gynecol Patho,2016,35:48.
9 Nakonechny QB,Gilks CB.Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes.Surg Pathol Clin,2016,189-199.
10 李晨,吴玉梅.卵巢癌与相关分子转移机制的研究进展.肿瘤学杂志,2015,21:61-65.
11 Pradeep S,Kim SW,Wu SY,et al.Hematogenous metastasis of ovarian cancer:rethinking mode of spread.Cancer Cell,2014,26:77-91.
12 杨娜,陈琦.血管内皮生长因子及其受体与卵巢癌相关性的研究进展.中国老年学,2017,37:491-494.
13 Nieman KM,Kenny HA,Penicka CV,et al.Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.Nat Med,2011,17:1498-1503.
14 Lengyel E,Burdette JE,Kenny HA,et al.Epithelial ovarian cancer experimental models.Oncogene,2014,33:3619-3633.
15 Divine LM,Nguyen MR,Meller E,et al.AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer.Oncotarget,2016,7:77291-77305.
16 Haemmerle M,Bottsfordmiller J,Pradeep S,et al.Abstract 5048:Platelet FAK is a critical regulator of tumor growth after withdrawal of anti-angiogenic therapy.Cancer Res,2016,76:5048-5048.
17 Carome M.FDA Warns Against Use of Ovarian Cancer Screening Tests.Health Letter,2016.
18 Jacobs IJ,Menon U,Ryan A,et al.Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening(UKCTOCS):a randomised controlled trial.Lancet,2016,387:945.
19 Unni SK,Schauerhamer MB,Deka R,et al.BRCA testing,treatment patterns and survival in platinum-sensitive recurrent ovarian cancer-an observational cohort study.J Ovarian Res,2016,3:9-18.
20 Harmsen MG,Inthout J,Arts-De JM,et al.Salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers:estimating ovarian cancer risk.Obstet Gynecol,2016,127:1054-1063.
21 Kwon JS,Tinker A,Pansegrau G,et al.Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.Obstet Gynecol,2013,121:14-24.
22 Patch AM,Christie EL,Etemadmoghadam D,et al.Whole-genome characterization of chemoresistant ovarian cancer.Nature,2015,521:489-494.
23 Zhang Y,Sriraman SK,Kenny HA,et al.Reversal of chemoresistance in ovarian cancer by co-delivery of a P-glycoprotein inhibitor and paclitaxel in a liposomal platform.Mol Cancer Ther,2016,15:2282-2293.
24 Wang S,Blois A,El Rayes T,et al.Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.Sci Transl Med,2016,8:329-334.
